Journal of Clinical Oncology
Articles in this Issue
Family awareness of genetic risk in affected Caucasian ancestry members with bladder cancer (BC) associated with germline variants in DNA‐repair genes (gDRGs).
868 Background: The aim of this study is to evaluate the awareness of Bladder Cancer (BC) in families with at least one af...
Impact of treatment approaches on survival in bulky node-positive penile squamous cell carcinoma: A National Cancer Database analysis.
3 Background: For patients with cN2–N3 penile squamous cell carcinoma (SCC), multimodal therapy with chemotherapy and surg...
Comparison of outcomes of contemporary immune-check point inhibitors combinations in Black patients versus White patients with metastatic renal cell carcinoma (mRCC).
433 Background: Immune checkpoint inhibitor (ICI)-based combinations, including dual ICI and ICI plus tyrosine kinase inhi...
Treatment utilization among patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in real-world US settings: A prostate cancer disease observation (PRECISION) data platform analysis.
75 Background: Although the number of life-prolonging treatment options for pts with mHSPC has increased, initial real-wor...
Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the JAVEMACS chart review study.
674 Background: Avelumab first-line maintenance (1LM) was approved in Japan in February 2021 based on the results of the p...
SASAN-SPARING: A phase 2 trial of sasanlimab maintenance as bladder-sparing option after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.
TPS900 Background: Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with a high risk of progression, repr...
Association of early achievement of ultra-low PSA levels with radiologic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC).
73 Background: Ultrasensitive assays allow the measurement of PSA levels below 0.2 ng/mL, which were previously considered...
Healthcare utilization and expenditure burden in bladder cancer: A nationally representative analysis (MEPS 2015–2022).
645 Background: Bladder Cancer (BCa) is recognized as a high-cost malignancy, largely from chronic disease course, recurre...
Use of active surveillance in young men with low-risk prostate cancer.
404 Background: Prostate cancer is the second most common cancer in men. The adoption of prostate specific antigen (PSA) s...
Post-operative pelvic lymph node radiation therapy in lymph node positive prostate cancer and mortality risk.
117 Background: Whether including pelvic lymph nodes in post-radical prostatectomy (RP) radiotherapy (RT) volume for patie...
Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.
700 Background: Urothelial cancer (UC) is the fifth most common cancer in Spain. Advanced UC (aUC) is an aggressive diseas...
Predictive value of a pathomics signature in <i>de novo</i> metastatic prostate cancer: An ancillary study of the PEACE-1 phase 3 trial.
221 Background: The addition of abiraterone acetate plus prednisone (AAP) to docetaxel and androgen deprivation therapy (A...
Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer.
245 Background: Residual cancer burden (RCB) in patients failing to achieve pathological complete response (non-pCR) after...
Incidence of immune-related adverse events (irAEs) and treatment discontinuation rates (TDR) in the adjuvant and metastatic setting in patients with urological malignancies: A systemic review and meta-analysis.
716 Background: Immune checkpoint inhibitors (ICI) are the standard treatment for numerous cancer types, in both the metas...
Obesity-associated epigenetic remodeling under androgen deprivation therapy: Implications for cardiometabolic risk in prostate cancer.
237 Background: Androgen deprivation therapy (ADT) is central to prostate cancer care but accelerates cardiometabolic toxi...
A phase II study of luxdegalutamide in combination with abiraterone in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
TPS275 Background: Androgen deprivation therapy (ADT) remains the cornerstone of mHSPC treatment, yet patients with high-v...
Randomized phase II trial of maintenance oral etoposide versus observation following high-dose chemotherapy and peripheral blood stem cell transplant in relapsed non-seminomatous germ cell tumors.
TPS625 Background: High-dose chemotherapy (HDCT) followed by peripheral-blood stem-cell transplant (PBSCT) remains an effe...
Efficacy of subsequent therapy in patients with metastatic renal cell carcinoma of intermediate and poor risk following first-line immuno-oncology combinations.
478 Background: In the era of immune-oncology (IO) combinations, specifically IO-IO or IO + tyrosine kinase inhibitors (TK...
Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer.
TPS276 Background: Metastatic castration-resistant prostate cancer (mCRPC) can evolve into a neuroendocrine-like subtype w...
Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial.
747 Background: The pioneering study was designed when platinum-based chemotherapy was the standard of care for advanced u...
Opening the black box: Biologic pathways underlying multimodal digital-pathology artificial intelligence in metastatic prostate cancer.
232 Background: Prostate cancer (PCa) spans indolent localized to lethal metastatic castration-resistant disease, undersco...
Early monitoring of derived neutrophil-to-lymphocyte ratio (dNLR) as a predictive biomarker of benefit to immune checkpoint inhibitors (ICI) in advanced clear cell renal cell carcinoma (ccRCC).
562 Background: Baseline high derived neutrophil-to-lymphocyte ratio (dNLR>3) has been associated with poor outcomes to...
Investigation of the PORTOS gene expression signature and the benefit of docetaxel in the ECOG-ACRIN E3805 CHAARTED randomized trial.
212 Background: The CHAARTED trial randomized men with metastatic hormone-sensitive prostate cancer (mHSPC) to either Andr...
Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.
541 Background: First-line pembro showed durable antitumor activity in pts with advanced ccRCC (cohort A) and non-ccRCC (c...
Population-level trends in radiation treatment of low-risk prostate cancer.
336 Background: Reducing overtreatment of localized prostate cancer remains a public health goal, particularly for patient...